跳至主要内容
临床试验/NCT04854785
NCT04854785已完成不适用

Imaging Neuroinflammation in COVID-19 and Persistent Depression With/Without Other Neuropsychiatric Symptoms

Centre for Addiction and Mental Health1 个研究点 分布在 1 个国家目标入组 77 人开始时间: 2021年6月14日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
77
试验地点
1
主要终点
Monoamine oxidase B total distribution volume in prefrontal cortex, anterior cingulate cortex, and hippocampus

研究概览

简要总结

The purpose of this study is to use state of the art brain imaging technology to investigate neuroinflammation in participants with depression after the respiratory symptoms of coronavirus disease 2019 (COVID-19) have passed.

详细描述

Participants will undergo two positron emission tomography (PET) scans: one [18F]FEPPA scan (for translocator protein (TSPO)) and one [11C]SL25.1188 scan (for monoamine oxidase B (MAO-B)) - as well as one magnetic resonance imaging (MRI) scan.

The primary hypotheses are:

  1. TSPO total distribution volume (TSPO VT) and MAO-B total distribution volume (MAO-B VT) are greater in the prefrontal cortex (PFC), anterior cingulate cortex (ACC), and hippocampus in COVID-19 with new onset, persistent major depressive episode (MDE) with or without other neuropsychiatric symptoms after recovery from mild respiratory symptoms (DNP-mild).
  2. TSPO VT and MAO-B VT are greater in the PFC, ACC, and hippocampus in COVID-19 with new onset, persistent MDE with or without other persistent neuropsychiatric symptoms after recovery from moderate respiratory symptoms (DNP-moderate).

Exploratory hypotheses are:

  1. Greater TSPO VT and MAO-B VT in the PFC, ACC, and hippocampus will be positively associated with severity of MDE symptoms and poorer performance on cognitive tasks.
  2. TSPO VT and MAO-B VT will be positively correlated in the PFC, ACC and hippocampus in COVID-DNP.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18 to 80
  • Diagnosis of COVID-19
  • Recovered from mild or moderate COVID-19 symptoms. Mild is defined as no evidence of pneumonia or hypoxia. Moderate is defined as presence of clinical symptoms of pneumonia but not severe enough to require ongoing use of supplementary oxygen.
  • Recovered from physical COVID-19 symptoms including cough, shortness of breath, fever, chills, or gastrointestinal upset for at least 4 weeks
  • New onset major depressive episode (MDE) within 3 months after COVID-19, as verified by the Research Version of Structured Clinical Interview for DSM 5 (SCID-5-RV)
  • High-affinity-binder (HAB) or mixed-affinity-binder (MAB) genotype for rs6971 polymorphism, based on saliva genetic testing

排除标准

  • Lifetime history of an autoimmune disease
  • Lifetime history of a neurological disease, excluding migraine
  • Lifetime diagnosis of Antisocial or Borderline Personality disorder
  • Lifetime history of psychotic symptoms prior to COVID-19
  • Lifetime diagnosis of Substance of Alcohol Use Disorder
  • Use of street drugs, including marijuana, in the past two months
  • Presence of cigarette smoking in the past two months
  • Positive urine drug or cotinine screen at any timepoint during the study
  • Currently pregnant
  • Currently breastfeeding
  • Use of aspirin or ibuprofen within the past 2 weeks
  • Use of any other anti-inflammatory medication or MAO-B inhibitors within the past 4 weeks
  • Use of herbal remedies in the past month
  • Presence of metal implant, object or electrical devices that are contraindicated for MRI
  • Current disorders of coagulation, blood or ongoing use of anticoagulant medication
  • Claustrophobia
  • Weight over 400lbs and height over 7ft
  • History of undergoing a number of PET scans that will lead participants to exceed the annual (20mSv) / lifetime (8 PET scans) radiation by completing this study
  • Current participation in another research study

结局指标

主要结局

Monoamine oxidase B total distribution volume in prefrontal cortex, anterior cingulate cortex, and hippocampus

时间窗: within 3 to 4 weeks after initiation of screening

PET scan measures in DNP-mild and DNP-moderate compared to healthy controls

Translocator protein total distribution volume in prefrontal cortex, anterior cingulate cortex, and hippocampus

时间窗: within 3 to 4 weeks after initiation of screening

PET scan measures in DNP-mild and DNP-moderate compared to healthy controls

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jeff Meyer

Program Head, Neurochemical Imaging for Mood Disorders

Centre for Addiction and Mental Health

研究点 (1)

Loading locations...

相似试验